So far, there is more preclinical evidence of the efficacy of anti-CD38-modified T cells, while some clinical studies investigating the efficacy and safety of anti-CD38 CAR–T cells in relapsed/refractory MM are in progress [32,33,34]. This evidence concerns the gene CD38 and Miyoshi myopathy.